Panoptes Pharma GmbH's selective dihydroorotate dehydrogenase inhibitor PP-001 could provide better efficacy and safety than standard corticosteroid therapy in autoimmune uveitis, where a new therapy hasn't been approved in decades. PP-001's dual mechanism and both local and systemic delivery could give it an advantage over more advanced molecules in development for uveitis.

Autoimmune uveitis is a form of intraocular inflammation primarily driven by Th1 and Th17 cells that produce a variety of proinflammatory cytokines. Th1 cells produce cytokines like interferon (IFN) gamma and TNF alpha, while Th17 cells generate interleukin 17 (IL-17), granulocyte macrophage colony-stimulating factor (GM-CSF; CSF2) and TNF alpha.